Scotiabank Issues Positive Forecast for NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price

NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) had its target price raised by Scotiabank from $47.00 to $52.00 in a report issued on Thursday morning,Benzinga reports. The brokerage currently has a sector outperform rating on the stock. A number of other analysts also recently weighed in on NAMS. HC Wainwright reissued a “buy” rating and issued […]

Mar 2, 2025 - 08:39

NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) had its target price raised by Scotiabank from $47.00 to $52.00 in a report issued on Thursday morning,Benzinga reports. The brokerage currently has a sector outperform rating on the stock. A number of other analysts also recently weighed in on NAMS. HC Wainwright reissued a “buy” rating and issued […]